| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH COMMUNICATION |
1 From the Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA (MLN, BS, CMU, and AM); the Department of Pediatrics, Medical University of South Carolina, Charleston, SC (BWH); the Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD (AA and RB-B); the Department of Preventive Medicine and Norris the Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA (LB and FG); the Division of Population Sciences, City of Hope Cancer National Medical Center, Duarte, CA (LB); the New Mexico Tumor Registry, University of New Mexico, Albuquerque, NM (SW); and the Department of Epidemiology and Population Health, School of Public Health and Information Sciences, University of Louisville, Louisville, KY (KB and RB)
Background:Little is known about vitamin D status in breast cancer survivors. This issue is important because vitamin D influences pathways related to carcinogenesis.
Objective:The objective of this report was to describe and understand vitamin D status in a breast cancer survivor cohort.
Design:Data are from the Health, Eating, Activity, and Lifestyle study. With the use of a cross-sectional design, we examined serum concentrations of 25-hydroxyvitamin D [25(OH)D] in 790 breast cancer survivors from western Washington state, New Mexico, and Los Angeles County. Cancer treatment data were obtained from Surveillance, Epidemiology, and End Results registries and medical records. Fasting blood, anthropometry, and lifestyle habits were collected after diagnosis and treatment. We examined distributions of 25(OH)D by race-ethnicity, season, geography, and clinical characteristics. Multivariate regression tested associations between 25(OH)D and stage of disease.
Results:Five hundred ninety-seven (75.6%) of the women had low serum 25(OH)D, suggesting vitamin D insufficiency or frank deficiency. The overall mean (±SD) was 24.8 ± 10.4 ng/mL, but it was lower for African Americans (18.1 ± 8.7 ng/mL) and Hispanics (22.1 ± 9.2 ng/mL). Women with localized (n = 424) or regional (n = 182) breast cancer had lower serum 25(OH)D than did women with in situ disease (n = 184) (P = 0.05 and P = 0.03, respectively). Multivariate regression models controlled for age, body mass index (in kg/m2), race-ethnicity, geography, season, physical activity, diet, and cancer treatments showed that stage of disease independently predicted serum 25(OH)D (P = 0.02).
Conclusions:In these breast cancer survivors, the prevalence of vitamin D insufficiency was high. Clinicians might consider monitoring vitamin D status in breast cancer patients, together with appropriate treatments, if necessary.
This article has been cited by other articles:
|
|
 |
|
  P. J. Goodwin Vitamin D in Cancer Patients: Above All, Do No Harm J. Clin. Oncol., May 1, 2009; 27(13): 2117 - 2119. [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Fabian If Vitamin D Prevents Breast Cancer, How Does It Do It, and How Much Does It Take? ASCO Educational Book, January 1, 2009; 2009(1): 71 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. C. Freedman and P. J. Goodwin The Role of Vitamin D in Breast Cancer Recurrence ASCO Educational Book, January 1, 2009; 2009(1): 79 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ligibel, W. Demark-Wahnefried, and P. J. Goodwin Diet, Exercise, and Supplements: Guidelines for Cancer Survivors ASCO Educational Book, January 1, 2009; 2009(1): 541 - 547. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
